Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Several possible studies

Story checked

AACR's annual cancer progress report highlights promising advances for patients (opens in a new tab)

medicalxpress.com · 2026-09-16

Short answerEvidenceSource

Short answer

Several possible studies

No clear answer.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Related research

Research nearby

The papers it could be

Nearby papers when the source is unclear.

and 12 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 8Not checkedAACR has released the 16th edition of its annual Cancer Progress Report, which reviews current data on cancer incidence, mortality and survivorship and describes how basic, translational, clinical and population science are improving health and saving lives.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 8Not checkedThe report highlights recent advances including 11 FDA-approved new anticancer therapeutics in the past year, plus new uses for five older drugs, a wearable noninvasive device for pancreatic cancer, an at-home HPV self-collection kit, and several AI-based tools for early detection and diagnosis.View evidenceHide evidence

As stated11 new anticancer therapeutics; 5 new uses

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 8Not checkedAccording to the report, reductions in smoking and advances in prevention, early detection and treatment contributed to a 35% decline in the overall U.S. cancer death rate between 1991 and 2024, corresponding to 4.8 million fewer cancer deaths.View evidenceHide evidence

As stated35% decline; 4.8 million fewer deaths

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 8Not checkedThe report says the five-year relative survival rate for distant-stage disease across all cancers combined has more than doubled over the past three decades, rising from 17% in the mid-1990s to 36% during 2016-2022.View evidenceHide evidence

As stated17% to 36%

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 8Not checkedIn its section on GLP-1 drugs and cancer risk, the report says a recent study found semaglutide use was associated with a 12% reduction in obesity-related cancer risk, and separate studies linked GLP-1 use in type 2 diabetes to lower risks of esophageal and colorectal cancer versus insulin therapy.View evidenceHide evidence

As stated12% reduction; 40% and 46% lower risk

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 8Not checkedThe report describes cancer vaccines as a promising treatment strategy and cites recent advances including a small individualized pancreatic cancer vaccine trial with durable remissions, an individualized mRNA neoantigen vaccine in melanoma associated with improved recurrence-free and distant metastasis-free survival, and a small clinical trial of Nous-209 in Lynch syndrome showing safety and a durable immune response.View evidenceHide evidence

As statedsmall trial; sustained improvements; durable remissions

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 7 of 8Not checkedThe report warns that cancer remains a major burden, estimating more than 2.1 million new U.S. cancer cases and more than 626,000 cancer deaths in 2026, with early-onset cancers rising globally and certain gastrointestinal cancers contributing disproportionately.View evidenceHide evidence

As stated2.1 million cases; 626,000 deaths; nearly 80% increase

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 8 of 8Not checkedAACR uses the report to call on Congress and other policymakers to protect and sustain federal cancer research funding, scientific merit-based grantmaking, and infrastructure that supports discovery, translation and access to care.View evidenceHide evidence

As statedat least $51.303 billion for NIH and at least $7.999 billion for NCI in fiscal year 2027

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 10 more candidates considered.